Royalty Pharma
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $564,690 | $537,267 | $567,978 | $596,000 |
Gross Profit | 563,036 | 531,267 | -15,622 | 519,487 |
EBITDA | 872,864 | 560,000 | 39,959 | 673,865 |
EBIT | 735,074 | 0 | -689,815 | 672,447 |
Net Income | 543,987 | 102,004 | 4,778 | 494,340 |
Net Change In Cash | 564,690 | 537,267 | 567,978 | 596,000 |
Free Cash Flow | 1,527,418 | -84,476 | 583,519 | -224,954 |
Cash | 950,052 | 1,764,644 | 843,000 | 477,010 |
Basic Shares | 592,726 | 596,912 | 597,479 | 446,568 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $2,354,554 | $2,237,215 | $2,289,463 | $2,122,000 |
Gross Profit | 1,793,898 | 2,231,545 | 2,266,467 | 2,033,889 |
EBITDA | 1,887,275 | 928,562 | 1,453,711 | 1,683,510 |
EBIT | 1,492,150 | 922,892 | 1,430,715 | 1,660,452 |
Net Income | 1,134,834 | 42,832 | 478,754 | 495,198 |
Net Change In Cash | 2,354,554 | 2,237,215 | 2,289,463 | 2,122,000 |
Cost of Revenue | 169,703 | 532,368 | 762,481 | |
Free Cash Flow | 2,987,802 | 4,185,132 | 2,018,059 | 4,231,629 |
Cash | 477,010 | 1,710,751 | 1,541,048 | 1,009,000 |
Basic Shares | 602,900 | 437,972 | 414,802 | 375,455 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | $1.01 |
2024-06-30 | $0.96 |
2024-03-31 | $0.98 |
2023-12-31 | $1.15 |
